Tuesday, June 2, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Hodgkin and Non-Hodgkin Lymphomas

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join Us on Tuesday, June 2
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.

 
 
Faculty

Kim Leake, MSN, FNP-C
UVA Health
Division of Hematology/Oncology
Emily Couric Clinical Cancer Center
Charlottesville, Virginia

Mollie Moran, APRN-CNP, AOCNP
The James Cancer Hospital at The Ohio State University
Columbus, Ohio


Craig Moskowitz, MD
Physician in Chief, Oncology Service Line
Sylvester Comprehensive Cancer Center
Professor of Medicine, Miller School of Medicine
University of Miami Health System
Miami, Florida

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
Physician Lead, Cancer Service Line
University of Virginia School of Medicine
Charlottesville, Virginia

Moderator

Neil Love, MD
Research To Practice
Miami, Florida


Topics for Discussion

  • Module 1: Mantle Cell Lymphoma
  • Module 2: Follicular Lymphoma
  • Module 3: Diffuse Large B-Cell Lymphoma
  • Module 4: Hodgkin Lymphoma
A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphomas.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL), and use this information to enhance therapeutic decision-making for patients.
  • Appraise the rationale for and available data documenting the utility of chemotherapy-free regimens for newly diagnosed and R/R FL, and use this information to counsel patients regarding what role, if any, these strategies should play in their care.
  • Recognize how prior therapeutic exposure and patient and disease characteristics can affect the selection and sequencing of available systemic treatments for patients with R/R FL and MCL.
  • Advise individuals with R/R DLBCL about clinical trial findings documenting the efficacy of polatuzumab vedotin in combination with bendamustine/rituximab and the recent FDA approval of this regimen.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor (CAR) T-cell therapy, and identify patients with R/R DLBCL and other lymphomas for whom this approach may be appropriate.
  • Consider the scientific rationale for the evaluation of brentuximab vedotin in combination with AVD (doxorubicin, vinblastine and dacarbazine), recall available clinical trial data with this regimen and discern how it can be optimally incorporated into the front-line management of advanced classical HL.
  • Appreciate the recent FDA approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone for previously untreated CD30-positive PTCL, and counsel patients about the risks and benefits of this novel regimen.
  • Educate patients about the side effects associated with approved therapies commonly employed in the management of FL, MCL, DLBCL, HL and PTCL, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Describe available and emerging data with other investigational agents and strategies currently under evaluation for FL, MCL, DLBCL, HL and PTCL, and as applicable, refer eligible patients for trial participation.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with Hodgkin and non-Hodgkin lymphomas to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/Lymphomas/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seattle Genetics.